Our group
An independent Group committed to therapeutic progress to serve patient needs.
35th
LARGEST PHARMACEUTICAL
GROUP WORLDWIDE
and 2nd largest pharmaceutical
Group in France*.
Close to 140
COUNTRIES in which the
Group’s medicines are distributed
Over 22,000
EMPLOYEES worldwide
*IQVIA, Analytics Link / World 76 countries – MAT Q1-2024
Servier, a global pharmaceutical group
Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day.
A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, Eastern Europe and Brazil. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle.
Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%).
Our vocation
We are committed to therapeutic progress to serve patient needs.
Our values
Date to innovate
Care
Grow by sharing
Commit to succeed
Our vision
Founded to serve health, our Group aspires to make a meaningful social impact for patients and for a sustainable world.
A comprehensive healthcare offering
Every day, Servier helps to treat patients in close to 140 countries using its extensive range of brand-name and generic medicines. In line with our conviction to offer a comprehensive range of health care solutions, we also provide e-health solutions that cover the entire patient journey.
Servier brand-name medicines
GENERIC MEDICINES
Research & Innovation
Our aim is clear—to pick up the pace of research and efforts to develop new therapeutic solutions guided by a long-term vision.
Day in, day out, our teams work tirelessly to discover and develop medicines where patient needs are greatest.
Servier’s governance model headed by a non-profit foundation aligns perfectly with the long-term perspective required for research and development. Our independence from market forces means we can invest heavily in R&D to innovate and develop new medicines.
That is why we invest close to 20% of our sales revenue (excl. generic medicines) each year in R&D.
Servier research & development institute in Paris-Saclay
In Paris-Saclay, Servier will be able to develop a more agile and open approach to R&D that centers even more closely around the patient to speed up the discovery of innovative therapeutic solutions.
- 2023 opening in 2023
- 45,000sqm a building spanning
- 1,500 employees
A partner of choice
Our partnership strategy centers around a single objective to ramp up the speed with which we develop treatments that significantly improve patients’ quality of life. We take a people-oriented approach to our partnerships, and we focus on creating win-win situations by pooling our expertise.
We are keen to invest in innovation that benefits patients in the future.
A strong industrial network
At our 14 production sites located throughout the world, we produce and distribute our medicines to the highest standards on quality, safety and reliability.
By harnessing digital innovation across the entire value chain, we continue to enhance our agility to meet patient demand.
Making a positive impact on society
The Group has adopted a proactive approach to Corporate Social Responsibility. This approach is structured around 4 CSR commitments that bring together 17 priority challenges, identified using a diagnosis based on ISO 26000 guidelines and interviews with stakeholders.
Since 2016, the Mécénat Servier Charity Fund has been supporting general interest initiatives in France and abroad in the fields of health care, education and community life. More information: https://mecenat.servier.com/